In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer2012 · 12,853 citations
2. 2Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates2010 · 2,975 citations
3. 3PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors2010 · 1,900 citations
4. 4The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors2008 · 470 citations
5. 5B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression2004 · 675 citations